Once a dose has been decided, one could then evaluate the efficacy of Foxy5 in combination, sequentially or simultaneously, with conventional therapies in the treatment of cancer patients with a low or no expression of the WNT5A protein in their primary tumor. The gene discussed is WNT5A; the disease is neoplasm.